Technology Webinars

The Future of qPCR:

Best practices, Standardization, and the MIQE Guidelines

This event occurred on Thursday, September 30, 2010
The main video player used on the Science Webinar system

Quantitative polymerase chain reaction (qPCR) has emerged as a powerful tool in molecular biology laboratories, both in research and in diagnostic settings. Even as qPCR grows in popularity, it is being recognized that there are some challenges associated with the technology, particularly with respect to reproducibility within and between laboratories. Fortunately, many of these limitations can be addressed through a standardized set of best practices. Using the recently published MIQE guidelines as a foundation, our expert panel will address the best practices of qPCR, with the goal of providing researchers with more consistent and reliable data.

During the webinar, the panelists will:

  •     Provide an overview of the MIQE guidelines.
  •     Address qPCR applications and primary challenges.
  •     Outline best practices and assay design to get the best out of your qPCR.
  •     Describe the essential quality control steps, including nucleic acid quantification.
  •     Answer your questions during the live Q&A session.
Speaker Bios

Stephen A. Bustin, Ph.D.

Queen Mary, University of London
London, UK 

Stephen Bustin obtained his Ph.D. in molecular genetics from Trinity College in Dublin and is currently Professor of Molecular Science at Barts and the London School of Medicine and Dentistry, a part of Queen Mary, University of London, and serves as Visiting Professor of Molecular Biology at the University of Middlesex. His research group’s general areas of interest are the small and large bowel, as well as colorectal cancer with particular emphasis on investigating the process of invasion and metastasis. An important aim is to translate molecular techniques into clinical practice by including molecular parameters into clinical tumor staging. He also has a special interest in real-time polymerase chain reactions (PCR) and has written and edited two books and published numerous peer-reviewed publications and book chapters on this subject. He advised the U.K. High Court and the U.S. Department of Justice on PCR technology in the measles, mumps, rubella (MMR) vaccine/Autism class action, and was an expert witness at the MMR trial in Washington, D.C. He coordinated the recent Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) initiative. 

Gregory L. Shipley, Ph.D.

University of Texas Health Science Center at Houston
Houston, TX 

Dr. Gregory Shipley completed both his undergraduate and graduate training at the University of California, Santa Barbara, after which he moved to the University of Florida in Gainesville and then to MIT in Cambridge, Massachusetts, to carry out his postdoctoral training. Following academic appointments at Texas A&M University and the University of Houston, Texas, Dr. Shipley moved to the University of Texas Health Science Center in Houston, Medical School in 1990, where he is currently the director of the Quantitative Genomics Core Laboratory. There he and his team perform quantitative protein assays using the MesoScale technology and multiple assay types utilizing real-time quantitative PCR. Dr. Shipley oversees the running and analysis of all real-time qPCR assays as well as the development of new assays. He publishes his work regularly and is also one of the authors of the MIQE (Minimum Information for Publication of Quantitative Real-Time PCR), together with Dr. Stephen Bustin. 

Manju R. Sethi

Thermo Fisher Scientific
Wilmington, DE

Manju Sethi joined Thermo Fisher Scientific in 2008, and as senior product manager is responsible for the development and management of its NanoDrop products line. Sethi specializes in the unique technology and workflow solution needs of life science customers and brings over 20 years of biotech and life science product management, as well as marketing and business development experience to the Thermo Fisher Scientific team. Previously, Sethi was a business consultant for various Fortune 100 companies and was also a senior member of the management team for the Qualicon biotech division at DuPont, where she served as the director of strategic planning and director of business development. Sethi holds a B.Tech. (ChemE) from the Indian Institute of Technology and an M.S. (ChemE) from Clarkson University.

Moderator: Sean Sanders, Ph.D.

Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Editor for Custom Publishing for the journal Science and Program Director for Outreach.